Evidence map›Paper›PMID 36345604›Full record

ArticleFEBS open bio2023

WDHD1 is over-expressed in nasopharyngeal carcinoma and may control the expression of ITGAV.

Ji-Yun Wu, Yi-Tong Niu, Su-Ning Huang, Yu-Min Tan, Zhen-Dong Yang, Ye-Ying Fang, Li Jiang, Ting-Ting Zhang, Xiao-Fen Zeng, Yun-Xi Peng and 3 more

Open access · goldAbstract read
In one paragraph

Article in FEBS open bio, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers.

0numbers the graph read from it
0cells of the map it votes in
7citing papers in PubMed
0.5field-weighted citation impact, top 42% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

7 citing papers in PubMed, 6 citations in OpenAlex.

  1. Article
  2. Review
  3. Article
  4. Article
  5. Article
  6. Article
  7. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors at 2 institutions in 1 country.

Ji-Yun WuDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yi-Tong NiuDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Su-Ning HuangDepartment of Radiotherapy, Guangxi Medical University Cancer Hospital, Nanning, China.
Yu-Min TanDepartment of Otolaryngology, First People's Hospital of Hechi City, Yizhou, China.
Zhen-Dong YangDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Ye-Ying FangDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Li JiangDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID 0000-0002-9894-2420
Ting-Ting ZhangDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Xiao-Fen ZengDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Yun-Xi PengDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Miao MoDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Cai-Xing LinDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.
Zhu-Xin WeiDepartment of Radiotherapy, First Affiliated Hospital of Guangxi Medical University, Nanning, China.ORCID 0000-0003-0630-1165
Guangxi Medical University · CNHechi University · CN

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Nasopharyngeal carcinoma (NPC) is a highly metastatic and invasive malignant tumor that originates in the nasopharynx. The DNA-binding protein WD repeat and HMG-box DNA-binding protein 1 (WDHD1) are highly expressed in a variety of tumours, but its expression and mechanism of action in NPC have not been reported to date. To investigate the involvement of WDHD1 in NPC, we first mined databases for the gene expression profile of NPC. Immunohistochemistry (IHC) was performed on 338 cases of NPC and 112 non-NPC samples to verify the results. We report that the expression of WDHD1 is significantly elevated in NPC. ChIP-seq was used to show that integrin alpha V (ITGAV) and WDHD1 exhibit a significant binding peak in the promoter region of the ITGAV gene. The expression levels of ITGAV and WDHD1 exhibit a significant positive correlation, and IHC was performed to show that ITGAV is highly expressed in NPC. Expression of ITGAV increased after overexpression of WDHD1, suggesting that ITGAV may be a potential target gene of WDHD1. Pathway analysis showed that both genes were closely related to the cell cycle, and flow cytometry was used to further confirm that decreased expression of WDHD1 significantly increased the number of apoptotic cells. In conclusion, our results suggest that expression of WDHD1 is increased in NPC and is likely to be associated with the NPC cell cycle; thus, we propose that WDHD1 may have the potential as a target gene for primary screening and treatment of NPC.

Indexed as

Integrin alphaVNasopharyngeal NeoplasmsCell Line, TumorDNA-Binding ProteinsHumansNasopharyngeal CarcinomaDNA-Binding ProteinsIntegrin alphaVWDHD1 protein, humanbioinformaticscell cycleimmunohistochemistrynasopharyngeal carcinomaWD repeat and HMG-box DNA binding protein 1

Identifiers

PMID36345604
PMCPMC9811654
OpenAlexW4308461576

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.